"uuid:ID","rationale","name","label","description","instanceType","id"
"38e888a9-ffa3-4f99-b98f-5410fb6a9fc3","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","Study Design 1","","The main design for the study","StudyDesign","StudyDesign_1"
